166 related articles for article (PubMed ID: 8439504)
21. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
Ralston SH; Alzaid AA; Gallacher SJ; Gardner MD; Cowan RA; Boyle IT
Q J Med; 1988 Oct; 68(258):825-34. PubMed ID: 3268894
[TBL] [Abstract][Full Text] [Related]
22. Clodronate in hypercalcemia of malignancy.
Bonjour JP; Rizzoli R
Calcif Tissue Int; 1990; 46 Suppl():S20-5. PubMed ID: 2137362
[TBL] [Abstract][Full Text] [Related]
23. Use of clodronate and calcitonin in hypercalcemia due to malignancy.
Ljunghall S
Recent Results Cancer Res; 1989; 116():40-5. PubMed ID: 2527399
[TBL] [Abstract][Full Text] [Related]
24. Treatment of malignant hypercalcaemia with clodronate.
Percival RC; Paterson AD; Yates AJ; Beard DJ; Douglas DL; Neal FE; Russell RG; Kanis JA
Br J Cancer; 1985 May; 51(5):665-9. PubMed ID: 3158326
[TBL] [Abstract][Full Text] [Related]
25. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Walls J; Ratcliffe WA; Howell A; Bundred NJ
Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
Flores JF; Rude RK; Chapman RA; Belani CP; Chang AY; Pritchard JD; Hoff JV
Cancer; 1994 May; 73(10):2527-34. PubMed ID: 8174049
[TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study.
Sabry NA; Habib EE
Med Oncol; 2011 Jun; 28(2):584-90. PubMed ID: 20204542
[TBL] [Abstract][Full Text] [Related]
28. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone.
Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD
Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597
[TBL] [Abstract][Full Text] [Related]
29. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
[TBL] [Abstract][Full Text] [Related]
30. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
[TBL] [Abstract][Full Text] [Related]
31. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
[TBL] [Abstract][Full Text] [Related]
32. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate.
Bonjour JP; Philippe J; Guelpa G; Bisetti A; Rizzoli R; Jung A; Rosini S; Kanis JA
Bone; 1988; 9(3):123-30. PubMed ID: 2971382
[TBL] [Abstract][Full Text] [Related]
33. Parenteral diphosphonates for treating malignant hypercalcemia.
Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
Cancer; 1981 Oct; 48(8):1922-5. PubMed ID: 6456809
[TBL] [Abstract][Full Text] [Related]
34. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity.
Walker P; Watanabe S; Lawlor P; Hanson J; Pereira J; Bruera E
Ann Oncol; 1997 Sep; 8(9):915-6. PubMed ID: 9358945
[TBL] [Abstract][Full Text] [Related]
35. Clodronate. A randomized study in the treatment of cancer-related hypercalcemia.
Witte RS; Koeller J; Davis TE; Benson AB; Durie BG; Lipton A; Stock JL; Citrin DL; Jacobs TP
Arch Intern Med; 1987 May; 147(5):937-9. PubMed ID: 2953318
[TBL] [Abstract][Full Text] [Related]
36. Comparison of three intravenous regimens of clodronate in Paget disease of bone.
Khan SA; McCloskey EV; Eyres KS; Nakatsuka K; Sirtori P; Orgee J; Coombes G; Kanis JA
J Bone Miner Res; 1996 Feb; 11(2):178-82. PubMed ID: 8822341
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of tumor hypercalcemia with clodronate. Effect on parathormone and calcitriol].
Scharla SH; Minne HW; Sattar P; Mende U; Blind E; Schmidt-Gayk H; Wüster C; Ho T; Ziegler R
Dtsch Med Wochenschr; 1987 Jul; 112(28-29):1121-5. PubMed ID: 2956079
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications.
Clemens MR; Fessele K; Heim ME
Ann Hematol; 1993 Mar; 66(3):141-6. PubMed ID: 8471660
[TBL] [Abstract][Full Text] [Related]
39. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
40. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
Yates AJ; Murray RM; Jerums GJ; Martin TJ
Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
